Novitas says Pacific Edge’s CxBladder tests are ‘not payable’

Novitas says Pacific Edge’s CxBladder tests are ‘not payable’
The company can continue to apply for renewed coverage. (Image: Pacific Edge)
Rebecca Howard
The long-awaited draft Local Coverage Determination from Novitas is not good news for Pacific Edge’s US business. According to the determination (LCD), “CxBladder tests are not reasonable and necessary to support positive outcomes in the management of bladder cancer and, therefore, are not payable”.In June 2023, Pacific Edge confirmed that the LCD from Novitas — its Medicare administrative contractor — meant its flagship Cxbladder test for bladder cancer didn’t meet the threshold required for coverage un...

More Markets

Surviving Trump's ‘whack-a-mole’ tariffs
Markets

Brian Robins: Surviving Trump's ‘whack-a-mole’ tariffs

Trump's end game is to curtail China's trade position.

NZ sharemarket up nearly 0.5%, third rise this week
Markets Market Close

NZ sharemarket up nearly 0.5%, third rise this week

The S&P/NZX 50 Index gained 56.99 points or 0.44% to 13,000.56.

Graham Skellern 16 Jan 2025
NZ sharemarket lifts off after Auckland Airport numbers
Markets Market close

NZ sharemarket lifts off after Auckland Airport numbers

The S&P/NZX 50 Index closed at 12,943.57, gaining 59.19 points or 0.46%.

Graham Skellern 15 Jan 2025
Auckland Airport numbers bounce back
Markets

Auckland Airport numbers bounce back

Numbers highest since the pandemic hit five years ago.

Staff reporters 15 Jan 2025